Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
Taylor recommends the right one for your goals and history at intake
Sometimes B12 is also included in the semaglutide injections to provide energy, promote metabolism, and increase weight loss
However, partial degradation often produces no visible change a vial stored incorrectly can appear clear and normal while containing 2030% aggregated peptide
But health insurers are reluctant to cover them and that has led to cost coming up very early in these conversations between doctors and their patients
